Changes in expression of WT1 during induced differentiation of the acute myeloid leukemia cell lines by treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid

Oncology Letters
Lili XiangZixing Chen

Abstract

The aim of the present study was to investigate the effect of 5-aza-2'-deoxycytidine (decitabine; DAC) and all-trans retinoic acid (ATRA) on Wilms' tumor 1 (WT1) in acute myeloid leukemia (AML) in vitro. The methylation status of the WT1 promoter was analyzed using methylation-specific polymerase chain reaction (MSP). The expression level of WT1 was detected by reverse transcription-quantitative polymerase chain reaction. The effect of DAC and ATRA on cell differentiation was evaluated by flow cytometry. The WT1 gene was methylated in U937 cells, but unmethylated in SHI-1 and K562 cells; the U937 cells did not express the WT1 gene, but the SHI-1 and K562 cells highly expressed the WT1 gene. DAC and ATRA, alone or in combination, exhibited no effect on the expression level of WT1 in the U937 cells and on the differentiation of the K562 cells. The combined treatment of DAC and ATRA markedly decreased the WT1 expression levels of the SHI-1 and K562 cells, and induced the differentiation of the SHI-1 and U937 cells. In the SHI-1 cells, WT1 expression changed inversely to the dynamic changes of cluster of differentiation 11b-positive rates. In conclusion, the combined treatment of DAC and ATRA has clinical therapeutic potential in a...Continue Reading

References

Aug 27, 1993·Cell·J A KreidbergR Jaenisch
Jul 22, 1997·Proceedings of the National Academy of Sciences of the United States of America·G B SilbersteinC W Daniel
Apr 1, 1999·Pediatric Hematology and Oncology·H J ImH Lee
May 25, 2001·International Journal of Hematology·H Sugiyama
Oct 12, 2001·Gene·V ScharnhorstA G Jochemsen
Mar 21, 2006·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Shin-ichi NakatsukaKatsuyuki Aozasa
May 26, 2007·Expert Reviews in Molecular Medicine·Suzie Ariyaratana, David M Loeb
Nov 6, 2007·Biochimica Et Biophysica Acta·Avril A MorrisonMichael R Ladomery
Jun 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David P SteensmaHagop Kantarjian
Jul 30, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria Teresa VosoGiuseppe Leone
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amanda F CashenJohn F DiPersio
Jun 14, 2013·Apoptosis : an International Journal on Programmed Cell Death·Jing YangAkihito Yokoyama

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.